Insulet Corporation (PODD)
Should You Continue to Retain PODD Stock in Your Portfolio Now?
Insulet's Omnipod 5 is set to drive growth in the upcoming quarters. Meanwhile, the stock is facing challenges due to economic uncertainties.
What Helped Insulet Stock Gain 10% This Week?
Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over this period.
Why Insulet Stock Was Zooming Higher This Week
The highly specialized medical device maker earns an important nod from a top regulator. A label expansion could potentially reach a market of 6 million people.
Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes
PODD marks a major milestone with Omnipod 5 approval for the treatment of type 2 diabetes.
This Healthcare Stock Is the Best Performer in the S&P 500 Tuesday
Insulet got a key FDA approval for an insulin delivery system.
These Two Stocks Plunged After Eli Lilly Drug Study Showed Diabetes Promise
Shares of Insulet (PODD) and DexCom (DXCM), two companies that provide medical devices for patients managing diabetes, tumbled Tuesday after a study showed that a popular drug made by Eli Lilly (LLY) significantly lowers the risk of developing type 2 diabetes.
Insulin Pump Maker Insulet's Stock Slumps on User Growth Concerns
Shares of Insulet (PODD) suffered the heaviest losses of any S&P 500 stock on Friday, dropping 8.8% after the maker of insulin management devices suggested new user growth could be lower than previously expected in the second half of 2024, despite topping second-quarter sales estimates.
Insulet Is the Worst Stock in S&P 500 Today, Despite Solid Earnings. Here's Why.
The automated insulin technology developer stock is on track for its largest percentage decline since February.
Insulin Pump Maker Insulet's Growth Catalysts Set to Boost Revenue in 2025: Analyst
Insulin device maker Insulet Corporation PODD reported a second-quarter adjusted EPS of $0.55 on Thursday, missing the consensus estimate of $0.56. It reported an EPS of $0.38 a year ago.
Insulet (PODD) Q2 Earnings Miss Estimates, '24 Sales View Raised
Insulet's (PODD) second-quarter performance benefits from the continued high demand for Omnipod 5.
Insulet Corporation (PODD) Q2 2024 Earnings Call Transcript
Insulet Corporation (NASDAQ:PODD ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President & Chief Executive Officer Ana Maria Chadwick - Executive Vice President & Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Jeff Johnson - Baird Larry Biegelsen - Wells Fargo Margaret Kaczor - William Blair Travis Steed - Bank of America Michael Polark - Wolfe Research Matt Taylor - Jefferies Chris Pasquale - Nephron Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Matthew O'Brien - Piper Sandler Steve Lichtman - Oppenheimer & Co. Joanne Wuensch - Citibank Operator Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Insulet inventory pressures cloud annual revenue forecast raise
Insulet Corp PODD.O on Thursday raised its annual revenue growth forecast but pressures over unutilised inventory clouded the upbeat outlook, sending shares of the insulin device maker down about 3.5% in extended trading.
